Clinical trial

Paracetamol Vs Paracetamol-Caffeine Association Vs Paracetamol-Codeine Association in the Management of Post Traumatic Pain in Emergencies

Name
Codeine-Cafeine-Paracetamol
Description
The purpose of this study is to: Compare the effect of paracetamol alone against Paracetamol+Codeine association against the association of paracetamol + Cafeine in the treatment of post-traumatic acute pain of the limbs.
Trial arms
Trial start
2022-11-01
Estimated PCD
2023-06-27
Trial end
2023-06-27
Status
Completed
Phase
Early phase I
Treatment
Paracetamol
21 pills will be provided with a preconised dose of 1 pill 3 times per day over 7 days period
Arms:
Paracétamol Group
Other names:
1000mg
Paracetamol Codeine
14 pills will be provided with a preconised dose of 1 pill 2 times per day over 7 days period
Arms:
Paracétamol Codéine Group
Other names:
500mg/ 30mg
Paracetamol caféine
21 pills will be provided with a preconised dose of 1 pill 3 times per day over 7 days period
Arms:
Paracétamol Caféine Group
Other names:
500mg/ 65mg
Size
1500
Primary endpoint
Delta Numerical Rating Scale (NRS) ( From 0 to 10 )
7 days from discharge
Eligibility criteria
Inclusion Criteria: * Age :18 years or older * Patients presented to the emergency department with acute post-traumatic pain and residual pain at rest and/or on movement with a numerical pain rating scale (NRS) \> 3/10 on discharge. * They all signed a written consent form. Exclusion criteria: * Self-mutilation * Severe acute trauma that may require hospitalization * Open or complicated fracture requiring surgical management * Regular use of analgesics * Any known allergy to paracetamol, caffeine or codeine * Asthma and acute/chronic respiratory insufficiency * Severe renal insufficiency (creatinine Cl\<30 ml/min) * Pregnant/lactating women * Hepatic cirrhosis. * Refusal, incapacity or difficulties to consent or to communicate
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'SINGLE', 'maskingDescription': 'study medications consists of a randomly sequence generated numbers.\n\npatients and the research associate who collected the outcome data are blinded from the study group', 'whoMasked': ['PARTICIPANT']}}, 'enrollmentInfo': {'count': 1500, 'type': 'ACTUAL'}}
Updated at
2023-06-28

1 organization

3 products

1 indication